Media headlines about Conatus Pharmaceuticals (NASDAQ:CNAT) have been trending positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Conatus Pharmaceuticals earned a media sentiment score of 0.31 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.8588451420471 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Shares of Conatus Pharmaceuticals (NASDAQ CNAT) opened at 5.69 on Tuesday. The company’s market cap is $170.72 million. Conatus Pharmaceuticals has a 12 month low of $1.45 and a 12 month high of $9.40. The firm’s 50 day moving average is $5.42 and its 200 day moving average is $5.74.

Conatus Pharmaceuticals (NASDAQ:CNAT) last issued its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). The firm had revenue of $10.00 million for the quarter, compared to the consensus estimate of $9.33 million. During the same quarter in the previous year, the business posted ($0.30) EPS. On average, equities analysts predict that Conatus Pharmaceuticals will post ($0.45) earnings per share for the current year.

Several research firms have issued reports on CNAT. Stifel Nicolaus reaffirmed a “buy” rating and set a $10.00 price objective on shares of Conatus Pharmaceuticals in a report on Thursday, August 3rd. ValuEngine raised Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 24th. Zacks Investment Research raised Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, July 24th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Conatus Pharmaceuticals in a report on Thursday, June 29th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $13.39.

TRADEMARK VIOLATION NOTICE: This piece was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/19/conatus-pharmaceuticals-cnat-given-media-impact-score-of-0-31.html.

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Insider Buying and Selling by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Stock Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.